Esteghamat Naseem, Tsumura Aaron, Marquez-Arreguin Gabriel, Tuscano Joseph
Division of Malignant Hematology, Cellular Therapy and Transplantation, University of California Davis Comprehensive Cancer Center, Sacramento, CA, United States.
Division of Hematology & Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, United States.
Front Oncol. 2024 Oct 22;14:1481950. doi: 10.3389/fonc.2024.1481950. eCollection 2024.
Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with poor prognosis and limited therapeutic options. High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHCT) was historically the curative-intent treatment for patients who demonstrated chemosensitivity to salvage therapy. However, a significant portion of patients do not make it autoHCT due to disease progression or overall fitness and eligibility. This is of particular concern in the older adult population. In recent years, significant advances in cellular therapies including chimeric antigen receptor (CAR) T-cells and bispecific antibodies, in addition to improvement in autoHCT tolerability, have allowed for additional treatment options for patients with R/R DLBCL. These novel therapies offer the potential for durable remissions and cure, and should be considered in older patients. We present a review focused on the safety and efficacy of cellular therapies in the older adult population with R/R DLBCL.
复发/难治性（R/R）弥漫性大B细胞淋巴瘤（DLBCL）是一种侵袭性疾病，预后较差，治疗选择有限。历史上，高剂量化疗联合自体造血干细胞移植（autoHCT）是对挽救治疗表现出化疗敏感性的患者的根治性治疗方法。然而，由于疾病进展或整体健康状况及符合条件情况，很大一部分患者无法进行autoHCT。这在老年人群中尤为令人担忧。近年来，除了autoHCT耐受性有所改善外，包括嵌合抗原受体（CAR）T细胞和双特异性抗体在内的细胞疗法取得了重大进展，为R/R DLBCL患者提供了更多治疗选择。这些新型疗法具有实现持久缓解和治愈的潜力，应在老年患者中予以考虑。我们发表了一篇综述，重点关注细胞疗法在老年R/R DLBCL患者中的安全性和疗效。
